Rebranding reflects advancing pipeline in next generation cancer immunotherapies, upcoming manufacturing expansion, and long-term corporate aspirationsThe.
16.05.2022 - Analysis of primary study endpoint was completed with 7 patients showing a measurable residual disease (MRD) response, of which 5 patients converted from MRD+ to MRD- and 2 patients showed a substantial, at least 10-fold reduction in MRD following . Seite 1
10.05.2022 - At the annual general meeting (the “AGM”) of Immunicum AB (publ), reg. no 556629-1786, (the “Company”), on 10 May 2022 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, . Seite 1